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Introduction 15
The rising incidence of Neisseria gonorrhoeae infection and antimicrobial resistance 16 imperils effective therapy for gonococcal infections (Centers for Disease Control and Prevention, 17 2018; Demczuk et al., 2015; Kirkcaldy et al., 2016) . Current first-line 18 therapy for gonorrhea relies on the extended spectrum cephalosporin ceftriaxone (CRO) as the 19 backbone of treatment. Dual therapy with azithromycin was intended to delay the emergence of 20 resistance, but rising azithromycin resistance rates have been reported 21 Public Health England, 2018) , resulting in revision of United Kingdom treatment guidelines to 22 CRO monotherapy (Fifer, Saunders, Soni, Sadiq, & FitzGerald, 2019) . With no clear next-line 23 agent, gonococcal resistance to ESCs is a problem of paramount clinical importance, illustrated 24 by recent reports of treatment failure and global spread of a multidrug-resistant strain (David W 25 David W Eyre et al., 2019) . 26
Rapid point-of-care diagnostics for antimicrobial susceptibility could help ensure 27 efficacious treatment and improve stewardship (Crofts, Gasparrini, & Dantas, 2017; Tuite et al., 28 2017) , with genotypic testing for known resistance determinants now implemented (Allan-Blitz 29 et al., 2017; Fifer et al., 2019) . In gonococcus, reduced susceptibility to ceftriaxone (CRO RS ) is 30 most commonly associated with genetic variation in penA (PBP2), the primary target of ESCs 31 (Kocaoglu & Carlson, 2015; Lindberg, Fredlund, Nicholas, & Unemo, 2007; David M. Whiley et 32 al., 2010; S. Zhao et al., 2009) . Because characterized penA alleles correlate very strongly with 33 phenotypic CRO RS in collections of clinical gonococcal isolates, the development of penA-34 targeted molecular diagnostic tests to rapidly evaluate gonococcal cephalosporin susceptibility is 35 underway (Deng, Allan-Blitz, & Klausner, 2019; L. Zhao, Liu, Li, & Zhao, 2019) . 36
However, these clinical collections often include isolates with ESC RS that is not 37 attributable to penA variation (Demczuk et al., 2015; Grad et al., 2016; Peng et al., 2019) . For 38 example, a recent report (Abrams et al., 2017) described the clinical gonococcal isolate 39 GCGS1095, which has a cefixime (CFX) minimum inhibitory concentration (MIC) of 1 μg/mL 40 and a CRO MIC of 0.5 µg/mL. These values are above the Center for Disease Control and 41
Prevention's Gonococcal Isolate Surveillance Project (GISP) threshold values for CFX RS 42 (0.25µg/mL) and CRO RS (0.125 μg/mL) . The type II (non-mosaic) penA 43 allele found in this isolate is not known to contribute to reduced cephalosporin susceptibility and 44 is found in many ESC susceptible isolates (D. M. Whiley, Limnios, Ray, Sloots, & Tapsall, 45 2007) . Loci distinct from penA can also contribute to ESC RS . These include mutations in porB 46 that decrease drug permeability, mutations that enhance drug efflux by the MtrCDE pump, and 47 non-mosaic mutations in penicillin-binding proteins (Lindberg et al., 2007; David M. Whiley et 48 al., 2010) . Mutations in pilQ have arisen during in vitro selection for cephalosporin resistance, 49 although these variants have not been observed in clinical isolates (Johnson et al., 2014) . 50
Considering these other resistance-associated loci in addition to penA has been proposed as a 51 way to refine sequence-based prediction of cephalosporin susceptibility (David W. Eyre et al., 52 2017) . However, the genotype of GCGS1095 at these loci does not explain its high-level CRO RS 53 phenotype (Abrams et al., 2017) . Rapid genotypic diagnostic tests for known resistance 54 mutations would therefore misclassify this strain as CRO susceptible. Defining the basis for 55 ESC RS in this isolate and others like it is critical for the development of robust sequence-based 56 diagnostics of antimicrobial susceptibility, for supporting public health genomic and phenotypic 57 surveillance programs, and for understanding the biology underlying cephalosporin resistance. 58
Here, we employed an experimental transformation-based approach to identify the 59 genetic basis of reduced susceptibility in three clinical isolates with high-level CRO RS . We found 60 that each of these isolates has unique mutations in the RNA polymerase holoenzyme (RNAP) 61 that cause CRO RS . One of these RNAP mutations is also present in a clinical isolate from the 62 U.K., belonging to a genetically distinct clade, that has otherwise unexplained CRO RS . We also 63 identified an additional two RNAP mutations that arose de novo to cause CRO RS in vitro. 64 Furthermore, introducing RNAP mutations into diverse clinical isolates from multiple lineages 65 was sufficient to cause high-level phenotypic CRO RS , underscoring the ability of isolates from 66 circulating clades to develop CRO RS via a single mutation in RNA polymerase. 67
Results

69
A single missense mutation in rpoB is the genetic basis for reduced ceftriaxone 70 susceptibility in the clinical isolate GCGS1095. 71
To identify the genetic basis of reduced susceptibility in GCGS1095, we transformed a 72 ceftriaxone susceptible (CRO S ) recipient strain with genomic DNA from GCGS1095. We 73 reasoned that minimizing the genetic distance between the resistant donor and susceptible 74 recipient would improve the likelihood of identifying the causative region for CRO RS and would 75 reduce potentially confounding effects of divergent genomic backgrounds. Consequently, we 76 selected GCGS0457, a close phylogenetic neighbor of GCGS1095 (Figure 1 ), as the CRO S 77 recipient for these experiments. Transformants were selected on CRO plates, and those that 78 acquired the CRO RS phenotype were characterized by whole genome sequencing to determine 79 which variants they had inherited from GCGS1095. 80
We recovered multiple CRO RS transformants. GCGS0457 did not develop spontaneous 81 CRO RS during culture or when transformed with autologous GCGS0457 genomic DNA. Whole 82 genome sequencing of the CRO RS transformants showed that each transformant inherited the 83 same single nucleotide polymorphism (SNP) in rpoB (nucleotide change G602A), which encodes 84 the RNA polymerase beta subunit RpoB (amino acid substitution R201H) ( Figure 2 ). We named 85 this allele rpoB1. These CRO RS transformants did not acquire variants in genes known to 86 contribute to reduced cephalosporin susceptibility, such as penA, ponA, pilQ, or mtr (David W. 87 Eyre et al., 2017) . 88
As RNA polymerase mutations have not been associated with cephalosporin resistance in 89
Neisseria, we tested whether the rpoB1 mutation is sufficient to confer CRO RS . To do so, we 90 performed directed transformation of GCGS0457 with a ~1.5 kilobase PCR product surrounding 91 the variant position of rpoB1. With the exception of the single rpoB G602A nucleotide change, 92 the sequence of this PCR product was identical to the parental GCGS0457 sequence. 93
Transformation with the rpoB1 allele amplified from GCGS1095 yielded multiple CRO RS 94 transformants, whereas transformation with control PCR products amplified from a strain 95 containing wild-type rpoB yielded none. Sanger sequencing confirmed the presence of the 96 expected SNP in each resistant transformant. Representative CRO RS transformants were further 97 examined by whole genome sequencing, which ruled out spontaneous mutations. The CRO MIC 98 of the rpoB1 transformant strain GCGS0457 RpoB R201H was 0.25 μg/mL, a more than ten-fold 99 increase from recipient strain GCGS0457 (CRO MIC 0.016 μg/mL) ( GCGS1014 is a phylogenetic neighbor of GCGS1095 that also has unexplained CRO RS 106 ( Figure 1 ; Table 1 ). The close phylogenetic relationship between these isolates led us to 107 hypothesize that they would share the same mechanism of CRO RS . However, the GCGS1014 108 isolate lacks the rpoB1 allele identified in GCGS1095. In fact, among the 1102 sequenced 109 isolates in the GISP collection, the rpoB1 allele is unique to GCGS1095 (Supplemental file 1). 110
To define the genetic basis of CRO RS in GCGS1014, we used the same unbiased 111 transformation approach as described above, again using the CRO S neighbor GCGS0457 as the 112 recipient strain. The CRO RS transformants from GCGS1014 gDNA did not have mutations in 113 rpoB or in other characterized resistance-associated genes. Instead, all CRO RS transformants 114 inherited a single nucleotide substitution in rpoD (nucleotide G292A), which encodes the major 115 housekeeping sigma factor RpoD, or σ 70 (amino acid substitution E98K) ( Figure 2 ). This allele, 116 rpoD1, is present in the CRO RS donor GCGS1014 but not in GCGS1095 (Table 1) or in any  117 other isolate from the GISP collection (Supplemental file 1). To test the ability of the rpoD1 118 allele to confer CRO RS to a susceptible strain, we transformed GCGS0457 with a ~1.5 kilobase 119 PCR product that includes the single variant position in rpoD1. As with the directed 120 transformation of rpoB1, the rpoD1 allele amplified from GCGS1014 transformed GCGS0457 to 121 high-level CRO RS , but control PCR products amplified from strains with wild-type rpoD did not. 122
The presence of the rpoD1 allele in resistant transformants was confirmed by Sanger sequencing 123 and by whole genome sequencing, which also ruled out the possibility of spontaneous mutations 124 causing the CRO RS phenotype. The rpoD1 transformant strain GCGS0457 RpoD E98K had a CRO 125 MIC of 0.125 μg/mL, similar to that of the parental CRO RS isolate GCGS1014 (Table 1) . 126
As the CRO RS phenotype in GCGS1095 and GCGS1014 is caused by distinct RNAP 127 mutations, we examined alleles of RNAP components in each of the 1102 genomes in the GISP 128 collection (Grad et al., 2016) to identify additional RNAP variants that might explain other cases 129 of uncharacterized CRO RS (Supplementary file 1). We found that the isolate GCGS1013 has a 130 12-basepair in-frame internal deletion in rpoD, resulting in the deletion of amino acids 92-95 131 ( Figure 2 ); GCGS1013 has a CRO RS phenotype but does not have a CRO RS -associated penA 132 allele (CRO MIC 0.125 μg/mL; Table 1 ). Transformation of this allele, rpoD2, into the 133 susceptible recipient GCGS0457 increased CRO resistance to 0.125 μg/mL ( Table 1 ). The rpoD2 134 allele is also present in a clinical gonococcal isolate from a recent United Kingdom strain 135 collection (De Silva et al., 2016) . This isolate, GCPH44 (genome accession number 136 SRR3360905), has a CRO RS phenotype (CRO MIC 0.125 μg/mL) and represents a distinct 137 phylogenetic lineage from that of GCGS1013 ( Figure 1 ). Like GCGS1013, the CRO RS 138 phenotype of GCPH44 is not attributable to variation in penA or other known resistance 139 determinants (Table 1) . 140
The amino acids deleted in the rpoD2 allele (Δ92-95) are in a similar region of the RpoD 141 protein as the single amino acid change in the rpoD1 allele (E98K) (Figure 2A ). This flexible 142 portion of the σ 70 1.1 domain is not included in published RNA polymerase holoenzyme crystal 143 structures. Modeling of E. coli RNAP predicts that σ 70 1.1 interacts with the DNA channel 144 formed by the β subunit encoded by rpoB prior to open complex formation (Murakami, 2013) . In 145 E. coli, the RpoB residue homologous to the substituted amino acid in rpoB1 (E. coli RpoB 146 R197) is located on the surface of the β lobe structure that makes up this same channel ( Figure  147 2B). Taken together, these results demonstrate that RNAP-mediated CRO RS has arisen multiple 148 times in clinical isolates of N. gonorrhoeae, and that these different mutations affect a similar 149 region of the RNAP holoenzyme. They may therefore act via a similar mechanism to effect 150 phenotypic CRO RS . 151 152 Clinical isolates from multiple lineages can achieve high-level CRO RS via a single 153 nucleotide change in rpoB. 154
The rpoB1 and rpoD1 alleles each differ from wild-type by a single nucleotide. The 155 ability of these mutations to cause high-level CRO RS when introduced into the susceptible strain 156 GCGS0457 indicates that some gonococcal isolates are a single-step mutation from CRO RS . 157
Because three of the four clinical isolates we identified with RNAP-mediated CRO RS are 158 clustered in one part of the gonococcal phylogeny ( Figure 1 ), we tested whether acquisition of 159 CRO RS via this pathway is limited to strains within this particular cladewhich would suggest 160 that one or more genetic background factors are requiredor whether RNAP mutation 161 represents a broadly accessible evolutionary trajectory to CRO RS . 162 To address this question, we sought to transform genetically diverse recipient strains to 163 CRO RS with the rpoB1 allele. In a panel of 17 clinical isolates from the GISP collection, we 164 found five additional recipients dispersed throughout the phylogeny that acquired phenotypic 165 CRO RS following directed transformation with rpoB1 ( Figure 1 ; Supplementary file 1). The 166 remaining 12 isolates, as well as the laboratory strain 28BL, did not readily produce CRO RS 167 rpoB1 transformants after 1-2 transformation attempts. These results indicate that genetic 168 background compatibility with this resistance mechanism is not limited to a single gonococcal 169 lineage or to recipients with particular alleles of any RNA polymerase component 170 While screening isolates for genetic compatibility with rpoB-mediated CRO RS in the 174 directed transformation experiments described above, we tested isolates in parallel for 175 spontaneous development of CRO RS . We found that the CRO S isolate GCGS0364, located in a 176 similar part of the phylogeny as the resistant isolates GCGS1095, GCGS1014, and GCGS1013 177 ( Figure 1 ), produced stably CRO RS derivatives when selected on CRO in vitro. Sanger 178 sequencing of the rpoB locus in two of these derivatives identified two different spontaneous 179 rpoB mutations: rpoB2 (nucleotide change C470T, amino acid change P157L) and rpoB3 180 (nucleotide change G473T, amino acid change G158V) ( Figure 2A ). These de novo RpoB 181 mutations are predicted to occur in the same β-sheet as the rpoB1 variant position (R201H) 182 identified in GCGS1095 ( Figure 2B ). Directed transformation of rpoB2 or rpoB3 into the 183 parental (CRO S ) GCGS0364 isolate conferred phenotypic CRO RS , increasing the CRO MIC 184 more than 20-fold from 0.023 μg/mL to 0.5-0.75 μg/mL (Table 1) . 185 186 RNAP-mediated CRO RS acts via a cephalosporin-specific mechanism. 187 As optimal function of RNA polymerase machinery is required for bacterial fitness, we 188 tested the hypothesis that these RNAP mutations are not specific cephalosporin resistance 189 mutations but instead cause a slow-growth or general stress response phenotype that 190 nonspecifically increases resistance to diverse classes of antimicrobial compounds. 191
As expected, the rpoB1, rpoD1, or rpoD2 alleles conferred reduced susceptibility to 192 cefixime (another third-generation cephalosporin) when transformed into the CRO S recipient 193 GCGS0457. However, these alleles did not affect susceptibility to antimicrobial drugs that do not 194 target the cell wall, including ciprofloxacin, tetracycline, azithromycin, and rifampicin. 195
Surprisingly, these mutations also failed to confer resistance to the non-cephalosporin β-lactams 196 penicillin and ertapenem. The apparent cephalosporin specificity of these RNAP mutations in the 197 GCGS0457 background is consistent with in the antibiotic susceptibility profiles of the three 198 clinical isolates from which they were identified (GCGS1095 for rpoB1, GCGS1014 for rpoD1, 199 and GCGS1013 for rpoD2) ( Table 2) . 200 GCGS0457 rpoB1 and GCGS0457 rpoD1 transformants were further examined for 201 evidence of a slow growth phenotype that might increase antibiotic tolerance. When grown on 202 GCB agar (Difco), neither of these transformants had a reduced growth rate compared to the 203 parental GCGS0457 strain ( Figure 3A ). Furthermore, the rpoB1 and rpoD1 transformants had no 204 gross defects in cell morphology by transmission electron microscopy (TEM) ( Figure 3B ), 205 although transformants were slightly smaller than the parental GCGS0457 strain (Supplementary 206 Figure 1 ). Taken together, these results do not support the hypothesis that RNAP mutations 207 reduce CRO susceptibility via a slow growth or nonspecific tolerance phenotype. 208 209 CRO RS -associated RNAP mutations induce widespread transcriptional changes. 210
To measure the functional effect of the rpoB1 and rpoD1 alleles on RNA polymerase, we 211 characterized the transcriptional profiles of the CRO RS isolates GCGS1095 (rpoB1) and 212 GCGS1014 (rpoD1) and the susceptible isolate GCGS0457 by RNA-seq. The transcriptional 213 profiles of the CRO RS isolates were similar to one another but distinct from GCGS0457 214 (Supplementary Figure 2) , with 1337 and 1410 annotated ORFs significantly altered in 215 abundance, respectively. The transcriptomic differences we observe may partly reflect the 216 genetic distance between these isolates (C. B. Wadsworth, Sater, Bhattacharyya, & Grad, 2019) , 217 as the resistant strains GCGS1095 and GCGS1014 are more closely related to one another than 218 they are to GCGS0457. We therefore compared GCGS0457 to its isogenic CRO RS transformants 219 GCGS0457 RpoB R201H and GCGS0457 RpoD E98K . The rpoB1 and rpoD1 alleles each profoundly 220 altered the transcriptional profile of GCGS0457: 1278 annotated ORFs in GCGS0457 RpoD E98K 221 and 1218 annotated ORFs in the GCGS0457 RpoB R201H were differentially expressed relative to 222 the parental GCGS0457 strain. The transcriptional profiles of the two transformants were very 223 similar to one another ( Supplementary Figure 2) , indicating that these different mutations have 224 similar functional consequences. Overall, a total of 890 annotated ORFs were differentially 225 expressed in all four CRO RS strains (the two CRO RS isolates and two transformants in the 226 GCGS0457 background) compared to GCGS0457. The vast majority of the transcriptional 227 changes are small in magnitude: 805/890 (90%) are less than 2-fold differentially expressed in 228 one or more of the CRO RS strains. 229
Altered expression of resistance-associated genes such as efflux pumps and β-lactamases 230 is a common mechanism of transcriptionally-mediated drug resistance. Although these strains 231 lack a TEM-1 β-lactamase (Grad et al., 2016) , increased expression of the gonococcal MtrCDE 232 efflux pump is known to increase resistance to β-lactams, including cephalosporins (Lindberg et 233 al., 2007) . However, transcription of the operon encoding this pump is not elevated in the CRO RS 234 RNAP mutants ( Supplementary Figure 3) , nor is it differentially upregulated in response to drug 235 exposure in these strains ( Supplementary Figure 4) . 236
In vitro evolution studies that evolve cephalosporin resistance in N. gonorrhoeae 237 identified inactivating mutations in the type IV pilus pore subunit PilQ (Johnson et al., 2014; S. 238 Zhao, Tobiason, Hu, Seifert, & Nicholas, 2005) , although similar pilQ mutations have not been 239 identified in clinical isolates, presumably because colonization requires pilus-mediated adhesion 240 to epithelial cells (Kellogg, Peacock, Deacon, Brown, & Pirkle, 1963; Rudel, van Putten, Gibbs, 241 Haas, & Meyer, 1992) . Notably, pilQ transcription is reduced in the GCGS0457 rpoB1 and 242 GCGS0457 rpoD1 transformants, as well as in the CRO RS isolates GCGS1095 and GCGS1014 243 ( Supplementary Figure 3 and 4) . The effect of hypomorphic pilQ expression on cephalosporin 244 susceptibility has not been described, but it is possible that reducing pilQ transcript levels may 245 confer the benefits of inactivating pilQ mutations without eliminating pilus-mediated attachment 246 and colonization altogether. 247
CRO RS -associated RNAP mutations alter the abundance of cell wall biosynthesis enzymes. 249
Since ESCs, like other β-lactams, block cell wall biosynthesis by covalently inhibiting 250 penicillin-binding proteins (PBPs), we examined how CRO RS -associated RNAP mutations affect 251 expression of enzymes in this target pathway. N. gonorrhoeae encodes four known PBPs 252 (Obergfell, Schaub, Priniski, Dillard, & Seifert, 2018; Sauvage, Kerff, Terrak, Ayala, & Charlier, 253 2008) : the essential high-molecular weight bifunctional transpeptidase/transglycosylase PBP1 254 (encoded by ponA); the essential high-molecular weight transpeptidase PBP2 (encoded by penA), 255 which is the primary target of ESCs (Kocaoglu & Carlson, 2015; S. Zhao et al., 2009) ; and the 256 nonessential carboxypeptidases PBP3 (encoded by dacB) and PBP4 (encoded by pbpG). In 257 addition to these canonical PBPs, N. gonorrhoeae genomes include DacC (encoded by dacC), a 258 third putative low-molecular weight carboxypeptidase that lacks conserved active site motifs 259 (Obergfell et al., 2018) . A homologue of the L,D-transpeptidase YnhG is also present in the 260 genome, although it has not been reported to be functional in N. gonorrhoeae. 261
Increased expression of drug targets can lead to decreased drug susceptibility, but 262 CRO RS -associated RNAP mutations did not increase mRNA or protein abundance of the CRO 263 target PBP2 (Figure 4 ). Transcription of the putative L,D-transpeptidase gene ynhG is also 264 unchanged in the CRO RS strains ( Supplementary Figure 3) . By contrast, PBP1 (ponA) is 265 upregulated in each of the CRO RS strains compared to GCGS0457, while expression of PBP3, 266 pbpG, and dacC is decreased in these strains ( Figure 4A-B ). Similar expression patterns were 267 observed in the presence of sub-inhibitory CRO ( Supplementary Figure 4) . 268
These altered PBP expression patterns are reflected in the cell wall structure of the 269 CRO RS strains: reduced expression of the carboxypeptidases results in more peptidoglycan with 270 pentapeptide stems ( Figure 5 and Supplementary Table 2 ), in agreement with reported structural 271 changes of cell walls from strains lacking the DacB carboxypeptidase (Obergfell et al., 2018) . 272
The increased expression of PBP1 in these RNAP mutants does not appear to increase the 273 abundance of crosslinked peptidoglycan (Supplementary Figure 5 and Supplementary Table 2 ). 274
Discussion 276
We have identified five different CRO RS -associated RNA polymerase alleles. Three of 277 these -rpoB1, rpoD1, and rpoD2are the genetic basis of high-level reduced ESC 278 susceptibility in clinical isolates with previously unexplained resistance phenotypes. The 279 remaining two arose spontaneously during culture, indicating that the RNAP alleles described in 280 this work are likely only a subset of functionally similar mutations that could arise in clinical 281
isolates. Clinical isolates from diverse genetic backgrounds can achieve high-level CRO RS via 282 these RNAP mutations. This is highlighted by the appearance of the rpoD2 allele in a second 283 clinical isolate belonging to a genetically distinct clade. Because this isolate is a member of a 284 large clade that includes many closely related isolates, this result illustrates the concerning 285 potential of these mutations to cause penA-independent CRO RS in globally distributed strains and 286 the importance of including these mutations in ongoing surveillance efforts. 287
Among the isolates of the GISP collection, there was no evidence for sustained 288 transmission of the CRO RS RNAP mutant isolates (Figure 1 ), perhaps indicating that fitness costs 289 associated with these RNAP variants have prevented their spread. However, it is important to 290 note that the CRO RS isolates GCGS1095, GCGS1014, and GCGS1013 are susceptible to 291 azithromycin ( Table 2 ). This susceptibility may be an alternative explanation for the failure of 292 these RNAP mutations to spread in an era of azithromycin/ceftriaxone combination therapy. 293 RNA polymerase mutations have been identified as mediators of diverse phenotypes, 294 such as reduced susceptibility to phage lysis (Atkinson & Gottesman, 1992; Obuchowski et al., 295 1997 ) and antimicrobial drugs, including cell wall biosynthesis inhibitors (Cui et al., 2010; 296 Kristich & Little, 2012; Y. H. Lee, Nam, & Helmann, 2013; Penwell et al., 2015; Wang et al., 297 2017) . These mutations often arise during in vitro evolution experiments, and are typically 298 described as artifacts of in vitro conditions, as the presumed pleiotropy of such mutations is 299 typically thought to be prohibitively deleterious. This description of resistance-associated RNAP 300 mutations in isolates collected from symptomatic patients demonstrates that, at least in the case 301 of CRO RS in N. gonorrhoeae, clinical isolates can acquire resistance via RNAP mutation while 302 still maintaining sufficient fitness to cause disease. Similar results have been reported regarding 303 the role of rpoB mutation in decreased susceptibility to vancomycin in staphylococcal species 304 (Guérillot et al., 2018; J. Y. H. Lee et al., 2018; Watanabe, Cui, Katayama, Kozue, & Hiramatsu, 305 2011). 306 In accordance with this model, the RNAP mutations identified in these CRO RS isolates 307 result in an apparently narrowly-targeted phenotypic change: RNAP mutants acquire resistance 308 to cephalosporins but not other classes of antimicrobial drugs, show no growth defect in vitro, 309 and display broad but small-magnitude changes to transcript levels, indicating that RNAP 310 mutation may be a valid approach to fine-tuning bacterial physiology for enhanced survival 311 under certain adverse conditions, such as antibiotic exposure. 312
The observation that the RNAP mutations identified here neither decrease susceptibility 313 to other antimicrobials nor alter growth phenotypes supports the hypothesis that these mutations 314 generate a "fine-tuning" cephalosporin-specific resistance mechanism, as opposed to a large-315 scale physiological shift toward a generally antibiotic-tolerant state. Altered activity of the RNA 316 polymerase transcription machinery likely results in this type of drug-specific reduced 317 susceptibility. RNAP variants differentially express multiple transcripts relating to the 318 cephalosporin mode of action. For example, while PBP2 levels are unaffected, the increase of 319 PBP1 expression may contribute to cephalosporin resistance. PBP1 and PBP2 both catalyze 320 transpeptidation, but PBP1 is not efficiently inhibited by third-generation cephalosporins 321 (Kocaoglu & Carlson, 2015) , suggesting that increased PBP1 levels may partly compensate for 322 CRO-inhibited PBP2 during drug treatment. The RNAP variants simultaneously reduce D,D-323 carboxypeptidase expression, increasing the pool of pentapeptide peptidoglycan monomers 324 available for transpeptidation by PBP1 and PBP2. Decreased expression of pilus pore 325 components in these mutants may also contribute to CRO RS by reducing permeability of the 326 outer membrane to cephalosporins (Chen et al., 2004; Johnson et al., 2014; Nandi, Swanson, 327 Tomberg, & Nicholas, 2015; S. Zhao et al.) . These expression changes and others may work 328 additively or synergistically to increase drug resistance. The pleiotropy of RNAP mutations may 329 thus enable a multicomponent resistance mechanism to emerge following a single genetic 330
change. 331
This result has important implications regarding the biology underlying cephalosporin 332 resistance, the potential for de novo evolution of resistance under cephalosporin monotherapy, 333 and the accuracy of sequence-based diagnostics. The identification of five independent mutations 334 in two separate components of the RNA polymerase machinery illustrates challenges faced by 335 computational genomics strategies to define new resistance alleles, especially because there are 336 other variants in these genessuch as rifampicin resistance mutations in rpoBthat do not 337 confer CRO RS . Continued isolate collection, phenotypic characterization, and traditional genetic 338 techniques will be critical for defining emerging resistance mechanisms (Hicks, Kissler, Lipsitch, 339 & Grad, 2019) . The observation that multiple lineages can gain CRO resistance through RNAP 340 mutations further underscores the need to monitor for the development of CRO RS through 341 pathways other than penA mutation, particularly as the ESCs are increasingly relied upon for 342 treatment. Identifying these alternative genetic mechanisms of reduced susceptibility is needed to 343 support the development of accurate and reliable sequence-based diagnostics that predict CRO 344 susceptibility, as well as to aid in the design of novel therapeutics. 345 346
Methods 347
Bacterial strains and culture conditions. Strains are presented in Supplementary Table 1 . 348
Except where otherwise specified, N. gonorrhoeae was cultured on GCB agar (Difco) with 349
Kellogg's supplements (GCB-K) (Kellogg et al., 1963) GCGS1095. Transformations were conducted in liquid culture as described (Morse, Johnson, 357 Biddle, & Roberts, 1986; Crista B Wadsworth, Arnold, Abdul Sater, & Grad, 2018) . Briefly, 358 piliated N. gonorrhoeae was suspended in GCP medium (15 g/L protease peptone 3, 1 g/L 359 soluble starch, 4 g/L dibasic K2HPO4, 1 g/L monobasic KH2PO4, 5 g/L NaCl) with Kellogg's 360 supplement, 10mM MgCl2, and approximately 100 ng genomic DNA. Suspensions were 361 incubated for 10 minutes at 37°C with 5% CO2. Transformants were allowed to recover on 362 nonselective agar for 4-5 hours. After recovery, transformants were plated on GCB-K 363 ceftriaxone gradient agar plates, which were prepared by allowing a 40 μL droplet of 5 μg/mL 364 ceftriaxone to dry onto a GCB-K agar plate. Transformations performed with GCGS0457 365 genomic DNA served as controls to monitor for spontaneous CRO RS mutation. After outgrowth 366 at 37°C in 5% CO2, colonies growing within the ceftriaxone zone of inhibition were subcultured 367 for further analysis. 368
Transformation of RNA polymerase mutations. ~1.5kb PCR fragments surrounding the rpoB 369 and rpoD loci of interest were amplified using the primer pairs RpoB-US (5'-370 ATGCCGTCTGAATATCAGATTGATGCGTACCGTT-3') and RpoB-DS (5'-371 CGTACTCGACGGTTGCCCAAG-3') or RpoD-US (5'-AACTGCTCGGACAGGAAGCG-3') 372
and RpoD-DS (5'-CGCGTTCGAGTTTGCGGATGTT-3'). The 12-bp DNA uptake sequence 373 (DUS) for N. gonorrhoeae (Ambur, Frye, & Tønjum, 2007 ) was added to the 5' end of the 374 RpoB-US primer (underlined) to enhance transformation efficiency with the PCR product; a 375 DUS was not added to the RpoD-US or RpoD-DS primers, as the PCR product amplified by 376 these primers includes two endogenous DUS regions. CRO S recipient strains were transformed 377 with 200-300 ng purified PCR products and transformants were selected for CRO RS as above. 378
Transformation reactions performed with wildtype alleles (rpoB + from GCGS1014; rpoD + from 379 GCGS1095) served as controls to monitor for spontaneous CRO RS mutation. 380
Sequencing and analysis. Following undirected transformation of GCGS0457 with GCGS1014 381 or GCGS1095 genomic DNA, or directed transformation of GCGS0457 with PCR products, 382 CRO RS transformants were analyzed by whole genome sequencing. Genomic DNA of 383 transformants was purified with the PureLink Genomic DNA Mini kit (Life Technologies) and 384 sequencing libraries were prepared as described (Kim et al., 2017) . Paired-end sequencing of 385 these libraries was performed on an Illumina MiniSeq (Illumina). Reads were aligned to the de 386 novo assembly of the GCGS0457 genome (European Nucleotide Archive, accession number 387 ERR855051) using bwa v0.7.8 (Li & Durbin, 2010) , and variant calling was performed with 388 pilon v1.22 (Walker et al., 2014) . 389
Whole genome assembly and annotation. Whole genome sequencing reads from the GISP 390 collection were assembled using Velvet (Zerbino & Birney, 2008) as previously described (Grad 391 2016) . Spades v 3.12 (Bankevich et al., 2012) was used for de novo assembly of GCPH44. 392 Contigs were corrected by mapping reads back to the assembly (--careful), and contigs with less 393 than 10X coverage or fewer than 500 nucleotides were removed. Reads were also mapped to the 394 reference genome NCCP11945 (NC_011035.1) with bwa mem v0.7.15 (Li, 2013) . Variants were 395 identified with Pilon v 1.16 (Walker et al., 2014) using a minimum depth of 10 and minimum 396 mapping quality of 20. SNPs, small deletions, and uncertain positions were incorporated into the 397 reference genome to create pseudogenomes. For each isolate in the GISP collection and in the 398 United Kingdom collection (De Silva et al., 2016) , the sequence of RNA polymerase 399 components was identified using BLASTn (ncbi-blast v2.2.30) (Supplemental File 1). 400
Phylogenetic analysis. Recombinant regions of the pseudogenome alignment were detected by 401
Gubbins (Croucher et al., 2015) , and the maximum likelihood phylogenetic tree was estimated 402 from this masked alignment using RAxML (Stamatakis, 2014) . The phylogeny was visualized 403 using ITOL (Letunic & Bork, 2019) . 404
Growth curves. Bacterial cells grown overnight on GCB-K plates were suspended in tryptic soy 405 broth to OD600 0.01. Three replicate GCB-K plates per time point were inoculated with 0.1 mL 406 of this suspension and incubated at 37°C with 5% CO2. At each time point, the lawn of bacterial 407 growth from each of three replicate plates was suspended in tryptic soy broth. Serial dilutions 408 were plated on GCB-K to determine total CFUs per plate. CFU counts were normalized to the 409 initial inoculum density (CFUs measured at time 0) for each replicate. 410
Transmission electron microscopy. Bacterial cells grown overnight on GCB-K plates were 411 suspended in liquid GCP medium with 1% Kellogg's supplement and 0.042% NaHCO3 to OD600 412 0.1. Suspensions were incubated at 37°C with aeration for 2 hours to allow cultures to return to 413 log phase. Cell pellets were collected by centrifugation and fixed for at least two hours at room 414 temperature in 0.2M cacodylate buffer with 2.5% paraformaldehyde, 5% glutaraldehyde, and 415 0.06% picric acid. Fixed pellets were washed in 0.1M cacodylate buffer and postfixed with 1% 416 Osmiumtetroxide (OsO4)/1.5% Potassiumferrocyanide (KFeCN6) for 1 hour, washed 2x in 417 water, 1x Maleate buffer (MB) 1x and incubated in 1% uranyl acetate in MB for 1hr followed by 418 2 washes in water and subsequent dehydration in grades of alcohol (10min each; 50%, 70%, 419 90%, 2x10min 100%). The samples were then put in propyleneoxide for 1 hr and infiltrated 420 ON in a 1:1 mixture of propyleneoxide and TAAB Epon (Marivac Canada Inc. St. 421 Laurent, Canada). The following day the samples were embedded in TAAB Epon and 422 polymerized at 60 degrees C for 48 hrs. Ultrathin sections (~60nm) were cut on a Reichert 423 Ultracut-S microtome, picked up on to copper grids stained with lead citrate and examined in a 424 JEOL 1200EX Transmission electron microscope or a TecnaiG² Spirit BioTWIN and images 425 were recorded with an AMT 2k CCD camera. 426
Transcriptomics. RNA isolation and sequencing was performed from N. gonorrhoeae strains as 427 described (Crista B Wadsworth et al., 2018) . Bacterial cells grown on GCB-K plates for 17 hours 428 were suspended in liquid GCP medium with 1% IsoVitaleX and 0.042% NaHCO3 to OD600 0.1. 429
Suspensions were incubated at 37°C with aeration for 2-3 hours to allow cultures to return to log 430 phase. Cells were collected to measure baseline transcriptional profiles. For samples measuring 431 the effect of drug exposure, 0.008 μg/mL CRO was added and cultures were incubated at 37°C 432 for an additional 90 minutes before cell collection. RNA was purified with the Direct-Zol kit 433 (Zymo). Transcriptome libraries were prepared at the Broad Institute at the Microbial 'Omics 434
Core using a modified version of the RNAtag-seq protocol (Rudy et al., 2015) . Five hundred 435 nanograms of total RNA was fragmented, depleted of genomic DNA, dephosphorylated, and 436 ligated to DNA adapters carrying 5'-AN8-3' barcodes of known sequence with a 5' phosphate 437 and a 3' blocking group. Barcoded RNAs were pooled and depleted of rRNA using the RiboZero 438 rRNA depletion kit (Epicentre). Pools of barcoded RNAs were converted to Illumina cDNA 439 libraries in two steps: (i) reverse transcription of the RNA using a primer designed to the 440 constant region of the barcoded adapter with addition of an adapter to the 3' end of the cDNA by 441 template switching using SMARTScribe (Clontech) as described previously (Zhu, Machleder, 442 Chenchik, Li, & Siebert, 2001) ; (ii) PCR amplification using primers whose 5' ends target the 443 constant regions of the 3' or 5' adapter and whose 3' ends contain the full Illumina P5 or P7 444 sequences. cDNA libraries were sequenced on the Illumina Nextseq 500 platform to generate 50-445 bp paired-end reads. Barcode sequences were removed, and reads were aligned to the FA1090 446 reference genome. Differential expression analysis was conducted in DESeq2 v.1.16.1 (Love, 447 Huber, & Anders, 2014) . 448
Sequence data availability. Genomic and transcriptomic read libraries are available from the 449 NCBI SRA database (accession number PRJNA540288). 450 PBP abundance measurement. Protein abundance of PBP1, PBP2, and PBP3 was calculated 451 using the fluorescent penicillin derivative bocillin-FL (Thermo Fisher). N. gonorrhoeae strains 452 from overnight cultures were suspended in liquid GCP medium supplemented with 1% 453 IsoVitalex and 0.042% NaHCO3 to a density of OD600 0.1. Suspensions were incubated with 454 aeration at 37°C for 2.5-3 hours. Bacterial cells were collected by centrifugation, washed once 455 with 1 mL of sterile phosphate-buffered saline (PBS), and resuspended in PBS 5 μg/mL bocillin-456 FL and 0.1% dimethyl sulfoxide (DMSO) to a final concentration of 1 mL of OD600 0.5 per 50 457 μL suspension. Bocillin-FL suspensions were incubated for 5 minutes. An equal volume 2x 458 SDS-PAGE sample buffer (Novex) was added and samples were boiled for 5 minutes. Proteins 459 in 30 μL of each suspension were separated by SDS-PAGE on 4-12% Tris-Glycine protein gels 460 (Novex), which were visualized on a Typhoon imager (Amersham) (excitation 488 nm/emission 461 526 nm) to detect bocillin-FL fluorescence. Densitometry was performed with ImageJ 462 (Schneider, Rasband, & Eliceiri, 2012) . Total bocillin-FL fluorescent signal was calculated for 463 each sample, and the proportional contribution of individual PBPs to this signal was reported. 464
Muropeptide analysis. N. gonorrhoeae strains were cultured for approximately 18 hours at 465 37°C with agitation in GCP medium supplemented with Kellogg's reagent and 0.042% NaHCO3. 466
Peptidoglycan was isolated and digested as described (Kühner, Stahl, Demircioglu, & Bertsche, 467 2014) with minor modifications. Briefly, bacterial cells were pelleted by centrifugation, 468 suspended in 1 mL 1M NaCl, and incubated at 100°C for 20 minutes. Samples were centrifuged 469 for one minute at 18,000×g. Pellets were washed three times with water, suspended in 1 mL 470 water, and placed in a bath sonicator for 30 minutes. 0.5 mL 0.1M Tris pH 6.8, 40 μg/mL RNase, 471 and 16 μg/mL DNase were added to each sample; samples were incubated with shaking at 37°C 472 for two hours, with the addition of 16 μg/mL trypsin after the first hour of incubation. Samples 473 were heated to 100°C for 5 minutes to inactivate enzymes, then centrifuged for 3 minutes at 474 18,000×g to pellet peptidoglycan. Pellets were washed with 1 mL aliquots of water until the 475 suspension pH measured between 5 and 5.5. Peptidoglycan was then resuspended in 0.2 mL 476 12.5mM NaH2PO4 pH 5.5 with 500 U/mL mutanolysin and incubated with shaking at 37°C for 477 16 hours. Samples were heated to 100°C for 5 minutes to inactivate mutanolysin and centrifuged 478 for 5 minutes at 18,000×g to pellet debris. The supernatant, containing solubilized muropeptides, 479 was removed to new tubes, and 50 μL 10mg/mL NaBH4 was added to each. Samples were 480 incubated at room temperature for 30 minutes and then the pH was adjusted to 2-3 with 85% 481 H3PO4. 482 LC-MS was conducted using an Agilent Technologies 1200 series HPLC in line with an 483
Agilent 6520 Q-TOF mass spectrometer operating with electrospray ionization (ESI) and in 484 positive ion mode. The muropeptide fragments were separated on a Waters Symmetry Shield 485 RP18 column (5 μm, 4.6 x 250 mm) using the following method: 0.5 mL/minute solvent A 486 (water, 0.1% formic acid) for 10 minutes followed by a linear gradient of 0% solvent B 487 1 . RNA polymerase-mediated reduced cephalosporin susceptibility among GISP isolates. Most high-level reduced cephalosporin susceptibility (MIC ≥ 0.125 μg/mL) in the GISP dataset is associated with the mosaic penA XXXIV allele, but some isolates with high MICs lack this allele (left). In four of these isolates -GCGS1095, GCGS1014, GCGS1013 (inset, redmarked leaves) and the U.K. isolate GCPH44 (left, orange circle) -CRO RS is caused by mutations in the RNA polymerase holoenzyme. Transformation of the CRO RS allele rpoB1 from GCGS1095 confers phenotypic reduced susceptibility to other susceptible clinical isolates (arrows and black-circled leaves, left) such as the phylogenetic neighbor GCGS0457 (inset, pinkmarked leaf). The isolate GCGS0364 (gray, denoted with *) spontaneously develops CRO RS via rpoB mutation in vitro. (Zuo & Steitz, 2015) , showing the location of the residues homologous to N. gonorrhoeae RpoB R201 (magenta), G158 (yellow), and P157 (orange). The flexible region of σ 70 1.1 that includes the variant positions of rpoD1 and rpoD1 is not included in this structure, but is predicted to interact with this region of RpoB (Murakami, 2013) . Normalized abundance of transcripts encoding penicillin binding proteins (PBPs) in parental isolates (GCGS0457, GCGS1095, GCGS1014) and RNAP mutant transformants in the GCGS0457 background, measured by RNAseq. (B) Relative protein abundance of PBP1, PBP2, and PBP3, as measured by bocillin-FL labeling. Total bocillin-FL signal for each strain was set at 100%. The relative contribution of each PBP to that signal is shown here. PBP4 protein was not observed on these gels, in agreement with previous reports (Zapun, Morlot, & Taha, 2016) .
Figure 5. Effect of CRO RS -associated RNA polymerase mutations on cell wall structure.
Relative abundance of muropeptide peaks in cell wall digests of GCGS0457 and its CRO RS derivatives, GCGS0457 RpoD E98K and GCGS0457 RpoB R201H . Transformant cell walls contain a higher proportion of peptidoglycan with pentapeptide stems (peaks 4, 7, 9, 14b, and 15) . Data is representative of 3 independent experiments. Values were calculated by extracting the peak mass from the total ion chromatogram, integrating the resulting peak area, and dividing by the sum of all of the peak areas within each sample. See Supplementary Table 2 for a list of all muropeptide masses detected. Figure 1 . Size and eccentricity of GCGS0457 and CRO RS transformants. 100-105 cellular cross sections from TEM images were manually measured in ImageJ to measure the (A) cross-sectional area and (B) eccentricity of cells from the CRO S strain GCGS0457 and its CRO RS transformants GCGS0457 RpoD E98K and GCGS0457 RpoB R201H . The cross-sectional area of CRO RS transformant cells is slightly smaller (mean area: 0.585 μm 2 for GCGS0457 RpoD E98K ; 0.621 μm 2 for GCGS0457 RpoB R201H ) than cells of the parental strain GCGS0457 (mean area 0.693 μm 2 ; p = 3.977x10 -5 compared to GCGS0457 RpoD E98K and p=0.00436 compared to GCGS0457 RpoB R201H by Welch's t-test). The degree of eccentricity in the CRO cells is not significantly different between these populations. Figure 2 . Principle components analysis of RNA-seq data. The first two principle components are shown for transcriptomic data collected from the CRO S isolate GCGS0457, the CRO RS isolates GCGS1095 and GCGS1014, and the CRO RS transformants GCGS0457 RpoD E98K and GCGS0457 RpoB R201H (three biological replicates/strain). Replicates from both CRO RS transformants cluster tightly, despite having different RNAP mutations.
Supplementary
repressor of the mtrCDE operon; ynhG, a putative L,D-transpeptidase; pilQ, which encodes the pilus pore subunit PilQ; and transcripts for each of the penicillin-binding proteins. (2) 
